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Abstract
Thecancer stemcell paradigmpostulates thatdysregulated tissue-specific stemcells or progenitor cells are precursors
for cancer biogenesis. Consequently, identifying cancer stem cells is crucial to our understanding of cancer progres-
sion and for the development of novel therapeutic agents. In this study, we demonstrate that the overexpression of
Twist in breast cells can promote the generation of a breast cancer stem cell phenotype characterized by the high
expression of CD44, little or no expression of CD24, and increased aldehyde dehydrogenase 1 activity, independent
of the epithelial-mesenchymal transition. In addition, Twist-overexpressing cells exhibit high efflux of Hoechst 33342
andRhodamine 123 as a result of increased expressionof ABCC1 (MRP1) transporters, a property of cancer stemcells.
Moreover, we show that transient expression of Twist can induce the stem cell phenotype in multiple breast cell lines
and that decreasingTwist expressionbyshort hairpinRNA in Twist-overexpressing transgenic cell linesMCF-10A/Twist
andMCF-7/Twist aswell as inMDA-MB-231 partially reverses the stem cell molecular signature. Importantly, we show
that inoculums of only 20 cells of the Twist-overexpressing CD44+/CD24-/low subpopulation are capable of forming
tumors in the mammary fat pad of severe combined immunodeficient mice. Finally, with respect to mechanism, we
provide data to indicate that Twist transcriptionally regulates CD24 expression in breast cancer cells. Taken together,
our data demonstrate the direct involvement of Twist in generating a breast cancer stem cell phenotype through
down-regulation of CD24 expression and independent of an epithelial-mesenchymal transition.
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Introduction
Tumor biogenesis and metastasis have classically been considered a re-
sult of random but sequential genetic alterations that lead to the selec-
tion and generation of clonal populations with uncontrollable growth
potential [1]. The cancer stem cell theory postulates that carcinogenesis
originates in tumor stem or progenitor cells possibly due to dysregula-
tion of normal stem cell self-renewal pathways [2]. Cancer stem cells are
capable of self-renewal and can differentiate into multiple cell types in
the tumor [3,4]. In addition, they possess high membrane transporter
[5] and telomerase activity [6] and have the ability to migrate and
metastasize [7]. Evidence supporting the cancer stem cell theory has
been demonstrated in hematological malignancies as well as in solid
tumors such as those of the prostate [8], colon [9], pancreas [10], brain
[11], and breast [12].
A subpopulation of breast cancer stem cells exhibits the phenotype
of high CD44, low CD24, and Lin− [12] and the ability to form
tumors in xenograft models with very few cell numbers [13]. However,
the identity of breast cancer stem cells is not limited to these molecular
signatures alone. The expression of aldehyde dehydrogenase 1 (ALDH),
which is also observed in hematopoietic progenitor cells, has been pro-
posed as a breast cancer stem cell marker [14,15]. Similarly, CD10, a
marker of myoepithelial precursors or bilinear progenitors that generates
both luminal and myoepithelial lineages, was identified as a marker of
potential breast cancer cell progenitors [16]. Thus, there is accumulating
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evidence indicating that markers of normal breast stem cells could be
additional markers of breast cancer stem cells.
Over the years, compelling evidence has revealed the oncogenic role
of Twist in breast cancer biogenesis [17–19]. Twist is a transcription
factor normally expressed only in mesodermal tissue in adults and is a
crucial master regulator during normal development [20]. However,
Twist up-regulation is observed in many cancers such as melanoma
[21], T-cell lymphoma [22], prostate cancer [23], gastric carcinomas
[24], rhabdomyosarcomas [25], and breast cancer [17]. Mechanistically,
overexpression of Twist has been shown to inhibit apoptosis and inter-
fere with p53 tumor suppressor functions [25,26].
Twist has also been associated with stem cell compartments during
embryogenesis [27].Overexpression ofmouseTwist in an in vitromouse
embryonic stem cell model system prevents premature muscle cell dif-
ferentiation, indicating its functions within the stem cell context [28]. In
addition, Twist has been described as a component of neural crest stem
cells [29]. In development, Twist has been shown to be upregulated
through the Sonic hedgehog/Patch pathway and in turn upregulates
Gli-1 [30]. This pathway is known to function in the self-renewal of
normal stem cells, in part through Gli-protein interactions [30].
Earlier work in our laboratory has demonstrated that overexpressing
Twist in breast cells increased invasiveness, motility, angiogenesis, and
resistance to radiation [26]. We also demonstrated that Twist is over-
expressed inmore than 60% of breast tumors [17] and is associated with
loss of E-cadherin expression [18] and increased genetic instability [19].
In the present study, we set out to identify and characterize the role
of Twist in generating breast cancer stem cells. To test this idea, we over-
expressed Twist in the breast adenocarcinoma cell lineMCF-7 as well as
in the transformed but nonmalignant breast cell line MCF-10A and
analyzed the resultant phenotypes for stem cell characteristics. We
found that overexpression of Twist significantly increased the stem cell
population, as identified by an increase in the number of CD44+/
CD24−/low and ALDH+ cells, increased exclusion of Hoechst 33342
and Rhodamine 123 dyes through increased expression of ABCC1
transporters, and initiated the formation of tumors from low-cell in-
oculums. Mechanistically, we found that Twist was a direct transcrip-
tional repressor of CD24 promoter activity. Taken together, these data
strongly support the role of Twist in generating breast cancer stem
cells and subsequent resistance to chemotherapy through increased
drug efflux.
Materials and Methods
Cell Culture
Cell lines were obtained from the American Type Culture Collection
(ATCC, Manassas, VA). Generation of the MCF-7/Twist cell line has
been described [17]. The MCF-10A/Twist cell line was prepared in a
similar fashion using the pCMV-Twist plasmid. For transient expres-
sion, cells were transfected using either retroviral constructs (generated
in-house) or lentiviral constructs (Open Biosystems, Huntsville, AL).
Flow Cytometry
Cells were washed in Hank’s balanced salt solution (HBSS) and har-
vested using 0.25% trypsin-EDTA (Invitrogen,Carlsbad,CA), counted,
and resuspended in 1% fetal calf serum (FCS)–phosphate-buffered
saline (PBS; 1 × 106 cells/400 μl). Cells were incubated with CD44–
fluorescein isothiocyanate (FITC) and CD24-phycoerythrin (PE; BD
Pharmingen, San Diego, CA), along with respective controls for 45 min-
utes at 4°C in the dark. After incubation, cells were centrifuged and re-
suspended in 500 μl of 1% FCS-PBS and acquired on a FACScan II
Cytometer (BD Immunocytometry Systems, San Jose,CA).No-antibody
and single-antibody controls were used to compensate the sample read-
ings and for designating quadrants. Analysis was done using Cell Quest
software (BD Immunocytometry Systems) on a Macintosh platform.
Efflux Assays
Semiconfluent cells were washed once with HBSS and resuspended
in growth medium at 1 × 106 cells/ml and 5 μg/ml Hoechst 33342
(Sigma-Aldrich, St. Louis, MO) and incubated for 45 minutes at
37°C in a constant-temperature water bath. Subsequently, the cells were
washed once in cold HBSS/2%BSA and resuspended in warmmedium
and incubated for 45 minutes at 37°C for efflux. Cells were centrifuged
and mounted on a slide before photomicroscopy.
For Rhodamine 123 (Sigma-Aldrich) staining, cells were trypsinized
and washed twice in PBS/1% FCS. One million cells were resuspended
in 100 μl of PBS/1% FCS and stained with 100 to 500 ng/ml Rhoda-
mine 123 for 15 to 30 minutes at 37°C. Cells were washed twice at
room temperature, resuspended, and incubated without Rhodamine
123 for 15 to 30 minutes at 37°C to allow for efflux to occur. Rhoda-
mine efflux was subsequently determined by flow cytometry on a
FACScan II flow cytometer.
ALDEFLUOR Assay
The ALDEFLUOR assay was performed as described by themanufac-
turer (Stem Cell Technologies, Vancouver, British Columbia, Canada).
Briefly, cells were harvested and resuspended in assay buffer at 1 ×
106 cells/ml and added to a tube containing 5 μl/ml of activated ALDE-
FLUOR substrate BAAA (BODIPY-aminoacetaldehyde). Half the
sample was transferred to a tube containing the ALDH inhibitor
diethylaminobenzaldehyde. Both samples were incubated at 37°C for
30 minutes. The cells were resuspended in assay buffer and assayed
on a FACScan II flow cytometer. The ALDH bright region was based
on the control diethylaminobenzaldehyde sample that was gated to have
less than five events.
Mammosphere Generation
Culture cells were harvested in trypsin-EDTA and carefully resus-
pended in mammary epithelial growth medium (Lonza, Walkersville,
MD). Cells were filtered through sterile filters (BD Discovery Labware,
Bedford, MA) to obtain a single cell suspension and plated at 5000 cells
per well of a six-well ultra low-attachment plate (Corning, Lowell, MA).
Mammospheres were assayed 3 to 10 days after cell plating. An average
of five fields/well was counted using ImagePro software (Media Cyber-
netics, Bethesda, MD), and experiments were done in quadruplicates.
Promoter Assays
The CD24 promoter (1600 bp) was polymerase chain reaction
(PCR)–amplified from human genomic DNA and cloned into the
pGL4 vector upstream of the luciferase reporter (Promega, Madison,
WI). Promoter assays were carried out in 24-well plates containing
50,000 cells. MCF-7 cells were transiently cotransfected with pGL4-
CD24 reporter construct, pEF1α-Twist plasmid, phRL-TK Renilla
control plasmid, and pCR3.1 nonspecific plasmid. After transfection,
the cells were incubated for varying times (12, 24, and 48 hours),
assayed using the dual luciferase kit (Promega), and quantified on
a luminometer (Berthold Sirius, Oak Ridge, TN).
Chromatin Immunoprecipitation
MCF-7/Twist cells were cross-linked with formaldehyde and
quenched with glycine. The cells were lysed to release chromatin, which
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was sheared by sonication to an average size of 500 to 1000 bp. The
chromatin was precleared with preblocked, formalin-fixed, heat-killed
Staphylococcus aureus cells. The positive control used was an anti–acetyl
histone H3 antibody (Millipore, Billerica, MA), whereas the negative
controls consisted of no-antibody and no-chromatin samples. The
antibody-chromatin–Staph A complexwas washed in stringent-buffered
conditions and eluted from the complex, reverse cross-linked at high
temperature, and phenol-chloroform extracted. The resulting purified
DNA was PCR-amplified using primers that flank the putative Twist
binding sites within the CD24 promoter.
Animal Experiments
Five to tenmillionMCF-7/Twist cells were labeledwithCD44-FITC
and CD24-PE antibodies as described earlier. Subsequently, the labeled
cells were sorted into CD44+/CD24−/low and CD44+/CD24+ sub-
populations using a FACSDiva flow cytometer. The cells were cultured
for one to two splittings before harvesting. The cells were trypsinized
and resuspended withmedia/Matrigel (1:1) before orthotopically inject-
ing various cell numbers in the mammary fat pad of 4- to 6-week-old
female severe combined immunodeficient (SCID) mice (National
Cancer Institute, Fredrick, MD). All animal experiments were con-
ducted in compliance with protocols instituted by the Institutional
Animal Care and Use Committee of the Johns Hopkins University
School of Medicine.
Immunohistochemistry
Immunohistochemistry was performed as described by us earlier [17].
Briefly, tumors were fixed overnight in 4% formalin and embedded
in paraffin for sectioning. Antigen retrieval was carried out by boiling
in sodium citrate for 10 minutes. Blocking was performed with normal
goat serum. Sections were incubated overnight with 1:50 dilution of
Twist primary antibody (in-house generated) and for 30 minutes with
secondary antirabbit biotinylated antibody (Vector Laboratories, Bur-
lingame, CA). Avidin-biotin mixture was added on the slides, followed
by detection with DAB followed by counterstaining with hematoxylin.
Sections were mounted using Permount (Thermo-Fisher Scientific,
Waltham, MA) and photographed on a Nikon Eclipse 80i fluorescence
microscope using a CoolSnap ES camera (Nikon Instruments).
Results
A CD44+/CD24−/low Subpopulation Is Evident in
Twist-Overexpressing Breast Cells
Recent studies have demonstrated that the cell surface expression
pattern of CD44 and CD24 constitutes a major identifying marker
of breast cancer stem cells. To determine the role of Twist in inducing
the breast cancer stem cell subpopulation, we overexpressed and
knocked down Twist in a panel of normal immortalized mammary
cells and breast cancer cell lines. MCF-10A/Twist, MCF-7/Twist,
and MDA-MB-231 cell lines were used as models for stable Twist
overexpression as well as for transiently knocking down Twist expres-
sion using short hairpin RNA (shRNA) lentiviral constructs. Parental
MCF-10A and MCF-7 cell lines were used as Twist-nonexpressing
models into which Twist was transiently expressed using retroviral con-
structs. Immunoblot analysis was used to determine the levels of Twist
expression in the transgenic cell lines as well as in Twist knockdown
cell lines. We obtained a significant decrease in Twist expression in
all three cell lines using shRNA lentiviral constructs (Figure 1A). Use
of empty vector controls did not alter the Twist expression levels in
these cell lines (data not shown).
The CD44+/CD24−/low subpopulation was evaluated by flow
cytometry in various parental cell lines (MCF-10A, MCF-7, MDA-
MB-231), transgenic cell lines (MCF-10A/Twist, MCF-7/Twist),
Twist-overexpressing cell lines (MCF-10A-Twist and MCF-7-Twist),
and in Twist knockdown breast cancer cell lines (MCF-10A/Twist-
shTwist, MCF-7/Twist-shTwist, MDA-MB-231-shTwist). As seen in
Figure 1B, we observed the nontumorigenic cell lines MCF-10A (3.1%)
and MCF-7 (0.0%) to have a low degree of the CD44+/CD24−/low
subpopulation. This is in comparison to the higher percentage of
CD44+/CD24−/low subpopulation in the metastatic MDA-MB-231 cell
line (78.5%) (top row). To evaluate if Twist-overexpressing breast
cancer cells have altered CD44 and CD24 expression, we analyzed
multiple MCF-10A/Twist and MCF-7/Twist clones for CD44 and
CD24 expression. As seen in the second row, MCF-10A/Twist cells
demonstrated increased CD44+/CD24−/low (73.3%) compared with
parental MCF-10A cells (3.1%). In addition, the MCF-7/Twist cell
line exhibited a higher CD44+/CD24−/low subpopulation (28.0%)
compared with parental MCF-7 cells (0.0%). To confirm that the ob-
served changes were caused by the effector functions of Twist and not
caused by clonal selection, we determined the CD44 and CD24 levels
in transient Twist-overexpressing breast cancer cell lines MCF-10A and
MCF-7. As seen in the third row, MCF-10A and MCF-7 transduced
with Twist showed an increase in the CD44+/CD24−/low subpopulation
(from 3.1% to 11.5% and from 0.0% to 4.2%, respectively).
Knockdown of Twist Reverses the Stem Cell Phenotype
Because Twist overexpression altered CD44 and CD24 expression
levels, we wanted to determine if decreasing Twist expression could
reverse the cancer stem cell phenotype back to parental status. Toward
this goal, we knocked down Twist expression in MCF-10A/Twist
and MCF-7/Twist cell lines, using lentiviral-mediated shRNA knock-
downs (Figure 1A). These cell lines showed lowered Twist expression
when compared with parental MCF-10A/Twist and MCF-7/Twist
cells. Subsequent analysis of the CD44+/CD24−/low subpopulation
by flow cytometry exhibited a loss in the CD44+/CD24− phenotype
in both Twist knockdown cell lines—MCF-10A/Twist (reduced
from 73.3% to 2.7%) and MCF-7/Twist (reduced from 28.0% to
11.7%; Figure 1B, fourth row). Knockdown of Twist expression in
MDA-MB-231 cells decreased the CD44+/CD24−/low subpopulation
from 78.5% in the parental cells to 55% in the knockdown cells
( fourth row). Collectively, these data demonstrate that Twist is a major
factor modulating the CD44+/CD24−/low subpopulation in breast
cancer cells.
With respect to epithelial-mesenchymal transition (EMT) markers
in Twist knockdown MCF-10A/Twist and MCF-7/Twist cells, we ob-
served an increase in E-cadherin levels but little or no change in vimentin
levels (Figure 2A). This further supports our hypothesis that Twist ex-
pression potentiates EMT and down-regulating Twist can partially
reverse this phenotype. In addition, we show that transient expression
of Twist in MCF-7 cells altered CD44 and CD24 levels but did not in-
duce any change in protein expression of the EMTmarkers E-cadherin
and vimentin (Figure 2B). This is in contrast to high vimentin and low
E-cadherin expression observed in stable Twist-expressing MCF-7 cells
(Figure 2B).
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MCF-7/Twist Cells Show Increased Efflux of Hoechst
33342 and Rhodamine 123 Dyes
A characteristic of stem cells is increased drug resistance brought
about by elevated expression of ATP-binding cassette (ABC) transport-
ers on the cell surface [31]. The functionality of these transporters can
be characterized by studying the efflux of vital dyes such as Hoechst
33342 and Rhodamine 123 from treated cells [32]. Because Twist
expression also induces chemoresistance [33], we initially evaluated
the ability of MCF-7/Twist cells to extrude Hoechst 33342 dye micro-
scopically [31]. As shown in Figure 3 (A and B), MCF-7/Twist cells
retained significantly less dye compared with parental MCF-7 cells
(relative fluorescence intensity per cell of 57 vs 65). To determine factors
responsible for increased efflux, we carried out quantitative reverse
transcription–PCR (qRT-PCR) for the expression of various stem cell
factors such as ABC transporters ABCG2 [31] and ABCC1 (MRP1)
[34]. The results obtained revealed a significant increase in ABCC1
(MRP1) and a lesser increase in ABCG2 transcript levels in Twist-
overexpressing breast cancer cells (Figure 3C ).
Subsequently, we confirmed the ability of MCF-7/Twist cells to
extrude Rhodamine 123 dye by analyzing mean fluorescence intensity
as determined by flow cytometry. As seen in Figure 3D, Rhodamine 123
was excluded more from MCF-7/Twist than the MCF-7 cells (96 vs
205). These results confirm that the chemoresistance of MCF-7/Twist
cells is partially conferred by the overexpression of at least one of the
transporter genes, ABCC1.
MCF-7/Twist Cells Have Increased Aldehyde
Dehydrogenase Activity
Expression of ALDH within the presumptive stem cell phenotype
identifies and enriches self-renewing populations within the breast
milieu [15]. Given our initial finding that the expression of Twist in
breast cells promotes the stem cell phenotype, we analyzed for ALDH
expression using the ALDEFLUOR assay (Stem Cell Technologies) in
a panel of breast cancer cell lines as well as in MCF-10A/Twist and
MCF-7/Twist transgenic cells. As shown in Figure 4 ( first row), the
percentage of ALDH-positive cells was generally low in the breast
cancer cell lines analyzed. However, stable expression of Twist increased
Figure 1. Cell surface expression of CD44 and CD24 in Twist-
dysregulated breast cells. (A) Immunoblots showing the down-
regulation of Twist in MCF-10A/Twist, MCF-7/Twist, and MDA-MB-231
breast cancer cell lines by short hairpin RNA against Twist delivered
using lentiviral vectors. Lower panels show Twist transient expres-
sion levels in MCF-10A and MCF-7 cell lines expressing Twist by
retroviral delivery. The antibody against Twist was generated in-
house and was validated. Actin was scored as loading control. (B)
Flow cytometry analysis of various cell lines for CD44 and CD24
expression. Unstained and single-antibody stained cells were used
as controls for setting the quadrants. The events in the lower right
quadrant represent the CD44+/CD24−/low subpopulation. The ana-
lyzed data are represented as dot plots of (first row) immortalized
normal mammary epithelial cell line MCF-10A and breast can-
cer cell lines MCF-7 and MDA-MB-231, (second row) stable Twist-
overexpressing cell lines MCF-10A/Twist and MCF-7/Twist, (third
row) transiently transduced Twist-expressing MCF-10A and MCF-7,
and (fourth row) Twist knockdown in MCF-10A/Twist, MCF-7/Twist,
and MDA-MB-231 breast cancer cells. Ten thousand viable cells
were gated for each dot plot acquisition. Results are representative
of five separate experiments.
Figure 2. Epithelial-mesenchymal marker expression in Twist cells.
(A) Immunoblots showing epithelial marker E-cadherin and mes-
enchymal marker vimentin in transient knockdown of Twist in stable
Twist-expressing cell lines MCF-10A/Twist and MCF-7/ Twist.
(B) Immunoblots showing E-cadherin and vimentin in MCF-7 and
MCF-7/Twist cells transiently expressing Twist. Transduced cells
were lysed and immunoblotted with antibodies against E-cadherin,
vimentin (Santa Cruz Biotechnology, Santa Cruz, CA), and Twist (in-
house generated). Actin (Sigma-Aldrich)was used as loading control.
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the ALDH-positive cells from 0.66% to 1.71% in MCF-10A/Twist
cells and from 0.04% to 2.81% in MCF-7/Twist cells (Figure 4, second
row). An increase in the ALDH-positive cells was also observed in
MCF-10A (from 0.66% up to 0.93%) and MCF-7 (from 0.04% up
to 1.2%) transduced with Twist-overexpressing retroviral constructs
(Figure 4, third row).
In further support of the role of Twist in altering ALDH activity, we
estimated ALDH in Twist knockdown cell lines. As shown in Figure 4
( fourth row), loss of Twist decreased the number of ALDH-positive
cells in MCF-10A/Twist (from 1.71% down to 0.13%) and MCF-7/
Twist (1.2% down to 0.86%). Interestingly, MDA-MB-231 has a very
low subpopulation of ALDH+ cells (0.01%), which is not affected by
Twist knockdown (data not shown). Overall, these results strengthen
our hypothesis that Twist is a regulator of the breast cancer stem
cell phenotype.
Ability of Self-renewal of the CD44+/CD24−/low Subpopulation
in MCF-7/Twist Cells
One of the defining characteristics of stem cells is the property of
self-renewal or asymmetric cell division. To ascertain whether the
ability of asymmetric division is an inherent characteristic of Twist+
cells, we flow sorted the CD44+/CD24−/low subpopulation from
MCF-7/Twist cells using antibodies against CD44 and CD24. After
purification, the enriched cells were allowed to divide in vitro, and the
CD44+/CD24−/low subpopulation was estimated at regular time inter-
vals. The initial percentage of the purified subpopulation of CD44+/
Figure 3. Efflux studies in MCF-7 and MCF-7/Twist cells. (A) Representative photomicrographs of Hoechst efflux staining in MCF-7/
Twist cells compared with parental MCF-7 cells. The cells, after efflux, were photographed using a Nikon Eclipse 80i fluorescence mi-
croscope. (B) Histogram showing quantification of fluorescence intensity per cell. Cell fluorescence (n = 6) in the blue channel was
analyzed using dedicated software developed in IDL programming environment that provides an operator-free segmentation of images
and determines the average relative fluorescence per cell. Three images were analyzed per sample. (C) Histogram showing expression of
drug transporters ABCG2, ABCC1, and ABCA1 in MCF-7/Twist and parental MCF-7 cells. (D) Histogram showing efflux of Rhodamine 123
stain in MCF-7/Twist and in MCF-7 cells. The amount of Rhodamine 123 dye in the cells was determined by flow cytometry. Results are
representative of three separate experiments.
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CD24−/low cells was greater than 98% (data not shown). As shown in
Figure 5A, continuous culture of the purified cells decreased the
CD44+/CD24−/low subpopulation from 72% (generation 2) to 31%
at generation 13, which is an indication of self-renewal that characterizes
the stem cell phenotype. After passage 15, the CD44+/CD24−/low sub-
population stabilized at 20% to 30% for the next 20 generations (data
not shown).
As a further confirmation of the cancer cell stem phenotype, we
carried out qRT-PCR for the expression of Twist, CD44, and CD24
transcript levels in the CD44+/CD24−/low and CD44+/CD24+ sub-
populations. CD24 expression was four-fold lower (P = .002) in the
CD44+/CD24−/low subpopulation compared with the CD44+/CD24+
subpopulation (Figure 5B). In addition, Twist expression was 15%
higher (P = .003) in the CD44+/CD24−/low subpopulation compared
with the CD44+/CD24+ subpopulation. No significant difference was
observed in the CD44 expression between these two subpopulations.
Increased Mammosphere Formation in
Twist-Overexpressing Cells
Because the ability to form mammospheres is a characteristic of
cancer stem cells, we evaluated the ability of MCF-10A/Twist and
MCF-7/Twist cells to form mammospheres in culture. MCF-7/Twist
cells formed mammospheres that were disaggregated and unlike the
classic rounded mammosphere phenotype observed in culture (Fig-
ure 5C). Similar results were reported using the highly aggressive breast
cancer cell line, MDA-MB-231, which also exhibits a large subpopu-
lation of CD44+/CD24−/low cells [35]. Nonetheless, these cells were
alive and present in significantly higher numbers (55 vs 30, P <
.0001) compared with parental MCF-7 cells when analyzed by the
Calcein-AM green staining (lower rows). With respect to MCF-10A/
Twist cells, significantly larger numbers of mammospheres (53 vs 32,
P = .002) were generated compared with the parental MCF-10A cells
(Figure 5D). This was observed in two independent MCF-10A/Twist
clones (data not shown). In addition, the mammospheres generated
using MCF-10A/Twist cells were significantly larger than the parental
MCF-10A cells.
Twist Downregulates CD24 Expression in Breast Cancer Cells
After the observation that Twist decreased CD24 expression, we
sought to characterize if this repression was transcriptionally regulated.
We analyzed the 1.6-kb CD24 promoter region for E-box sequences
(CANNTG) to which Twist can potentially bind. As shown in Fig-
ure 6A, the putative CD24 promoter contains eight E-box sequences.
This region was PCR-amplified and cloned into the pGL4 luciferase
reporter plasmid (Promega). Transient transfection assays using the
CD24 promoter-reporter construct and a Twist expression plasmid in
MCF-7 cells showed a significant down-regulation of the reporter gene,
24 and 48 hours after transfection (Figure 6B). A further confirmation
of this regulation was demonstrated using protein extracts fromMCF-7/
Twist cells and scored for CD24 protein levels. As shown in Figure 6C ,
CD24 protein expression was significantly reduced in MCF-7/Twist
compared with parental MCF-7 cells.
Twist Binds In Vivo to E-box Sequences in the CD24 Promoter
To establish that the down-regulation of CD24 by Twist was due to
the direct binding of Twist to the CD24 promoter sequence, we per-
formed chromatin immunoprecipitation (ChIP) assays using MCF-7
cells overexpressing Twist (Figure 6D). A set of PCR primers (5′-TGCCC-
CTTAGAATTGCTGTT-3′ and5′-TCATTGAACCTGGAAGTGG-3′)
was designed for specific amplification of the Twist binding sites (E-boxes)
from −1256 and −1107 bp within the CD24 promoter. As shown in
Figure 6D, the use of this primer set in PCR of ChIP DNA generated
from Twist immunoprecipitations resulted in a specific amplified product
Figure 4. ALDH activity in Twist-dysregulated breast cells. Dot plots
of various cell lines analyzed by flow cytometry for ALDH activity.
Cells were treated with ALDEFLUOR in the presence or absence of
ALDH inhibitor DEAB. After treatment, the samples were analyzed
by flow cytometry for the presence of ALDH bright cells. The ALDH
bright regionwas based on the control DEAB sample that was gated
to have less than five events. The cell percentage numbers for ALDH
positivity are indicated in the bottom right of each histogram. The
values presented are the averages of three independent experi-
ments. The analyzed data are represented as dot plots of (first row)
parental MCF-10A and MCF-7 breast cancer cell lines, (second row)
stable Twist-overexpressing MCF-10A/Twist and MCF-7/Twist
breast cancer cell lines, (third row) breast cell lines MCF-10A and
MCF-7 transiently transduced with Twist-expressing retroviral con-
structs, and (fourth row) Twist knockdown breast cancer cell lines
MCF-10A/Twist and MCF-7/Twist. Results are representative of five
separate experiments.
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Figure 5. Self-renewal and mammosphere formation of Twist-expressing MCF-7 cells. MCF-7/Twist cells were stained with CD44 and
CD24 antibodies and flow sorted to purify the CD44+/CD24−/low subpopulation. The purified MCF-7/Twist CD44+/CD24−/ low subpopulation
was propagated in culture, and the percentage of CD44 and CD24 cells was estimated by flow cytometry. (A) Histograms of chronological
changes in the CD44+/CD24−/ low subpopulation during a period of 13 generations. (B) qRT-PCR analysis of Twist, CD44, and CD24 transcript
levels in the purified CD44+/CD24−/ low versus CD44+/CD24+ subpopulations of cells. (C and D) Mammosphere formation by stable Twist-
overexpressing cell lines, MCF-7/Twist, and MCF-10A/Twist. Top rows show phase-contrast photomicrographs of mammospheres at a
magnification of ×20. The lower rows show viability of the cells as indicated by the fluorescence of Calcein-AM stain. Data are represented
as histograms on the right. Experiments were performed in quadruplicates and an average of five fields per well were counted.
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of 149 bp, whereas no amplification was seen in the samples that were
processed in the absence of precipitating antibody or no input chromatin.
We confirmed the PCR by qRT-PCR amplification (Figure 6E ). These
results indicate that Twist binds directly or as part of a complex to the
endogenous CD24 promoter in vivo.
Twist+/CD44+/CD24−/low Subpopulation Exhibits Increased
Tumorigenic Potential In Vivo
A hallmark of cancer stem cells is the ability to form tumors with
limited number of cells. To determine the minimum number of cells
of the Twist+/CD44+/CD24−/low subpopulation required to initiate
and establish tumor growth within the mammary fat pad, we injected
100, 50, and 20 purified cells into the orthotopic site in SCID mice.
We also injected 100 cells of the Twist+/CD44+/CD24+ purified sub-
population. After an incubation period of 7 weeks, we observed tumor
growth in mice injected with 20 cells (Figure 7A). There was a trend
toward increased latency as the cell inoculums became smaller with
tumor uptake time being approximately 2 to 3 weeks less in the
100-cell inoculums of the Twist+/CD44+/CD24−/low subpopulation
compared with that of the Twist+/CD44+/CD24+ subpopulation.
To study the expression levels of Twist in both theCD44+/CD24−/low–
and the CD44+/CD24+–derived tumors, we performed immunohisto-
chemistry on tumor sections. We found that tumors generated from
the Twist+/CD44+/CD24+ subpopulation had lower Twist expression
compared with tumors derived from the Twist+/CD44+/CD24−/low sub-
population (Figure 7B).
Discussion
Tumor origin has classically been conceived as a result of an accumu-
lation of mutations within the breast epithelium that cause cells to
escape cell death and maintain the mutator phenotype [1,36]. The
cancer stem cell theory postulates that these mutations or other cellular
changes occur in subpopulations of long-lived cancer stem cells, which
are the origin of tumorigenesis [2]. Initial identification of breast
Figure 6. Twist transcriptional regulation of CD24 expression. (A) Schematic representation of the CD24 promoter sequence showing the
location of putative TWIST binding sites relative to the transcription start site (+1). Tick marks denote the canonical E-box sequences
(CANNTG) to which Twist can potentially bind. The numbers above the tick marks indicate the relative position of E-box sequences within
the promoter region. (B) Reporter assays were performed using CD24 promoter-reporter constructs inMCF-7 with exogenous Twist expres-
sion plasmid added and estimated for 2 days. The results of the promoter assays are represented as a histogram showing normalized
luciferase readings in CD24 promoter activity. (C) Immunoblot analysis of cell extracts from MCF-7 and MCF-7/Twist cells scored for
CD24 (Santa Cruz Biotechnology) and Twist protein expression. Actinwas used as a loading control. (D and E) In vivo binding of Twist protein
to the CD24 promoter sequence. ChIP was carried out usingMCF-7/Twist cells and analyzed using CD24 promoter-specific primers by PCR.
Identical volumes from the final precipitate were used for the PCRs except for the input, which was diluted 10-fold.
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cancer stem cells was based on a combination of CD44+, CD24−, and
Lin−markers [12]. Subpopulations purified based on these markers had
a 10- to 50-fold increase in the ability to form tumors in NOD/SCID
mice. Subsequently, a number of markers have been defined such as
ALDH [15], CD10 [16], and CD133 [37].
On the basis of the need to identify novel breast cancer stem cell
markers, investigators have demonstrated that an in vitro EMT can in-
duce stem cell phenotypes [38]. However, the ontogeny of generating
the stem cell phenotype, before the onset of EMT, has not been deter-
mined. Moreover, the occurrence of EMT in breast cancers is itself
extremely rare [39], and the role of Twist and Snail as causal factors
has only been demonstrated in vitro [17,38]. This is the first report of
Twist mechanistically inducing the stem cell phenotype in breast cancer
cells. On the basis of our results using transient Twist-overexpressing
cells, we observed dysregulation of CD44 and CD24 expression before
any biochemical evidence of EMT. These data indicate that generation
of the breast cancer stem cell phenotype by Twist precedes an EMT
within our experimental settings. It is possible that Twist regulates other
factors that are expressed during stable Twist expression, which may
be absent during transient Twist expression. These factors may be one
reason why stable Twist expression leads to a higher CD44/CD24
subpopulation compared with transient Twist expression. Another pos-
sible explanation is that genetic changes induced early during tumor
biogenesis provide a transient state for cellular adaptation resulting in
the low expression of unique molecular markers including those of
cancer stem cells. Subsequent evolution of these cells and escape from
cellular senescence result in the establishment of stem cell markers in a
clonal population that is distinct from the bulk of the tumor resulting in
a larger percentage of cells with CD44+/CD24−/low expression.
In our present study, we demonstrate that Twist expression in breast
cells can augment the CD44+/CD24−/low or breast cancer stem cell. The
significance of this finding is that loss of CD24 in breast cancer patients
along with increased CD44 expression may promote metastasis [13].
Our results conclusively demonstrate that Twist binds directly or as part
of a complex to the endogenous CD24 promoter in vivo causing it to be
transcriptionally downregulated. This is supported by flow cytometry
data, which demonstrate a loss of CD24 in breast cancer cells with
Twist expression. This observation, in combination with the finding
that Twist expression is increased in high-grade breast tumors [17],
may provide a link between the loss of CD24 expression and the breast
cancer stem cell phenotype. Conversely, it is also possible that Twist
directly acts on CD44 because there is a distinct increase in CD44 ex-
pression in Twist-overexpressing cells as determined by flow cytometry.
Overall, this establishes Twist expression as one of the key factors that
directly drives cells toward a CD44+/CD24−/low phenotype or at least is
necessary for its maintenance.
Twist overexpression has been correlated with drug resistance to
microtubule-targeting anticancer drugs taxol and vincristine [33]. This
is significant in that ABCC1 (MRP1) is the major drug efflux pump for
vincristine [34]. Our results are the first direct evidence demonstrating
the increased ABCC1 transporter levels in Twist-overexpressing cells
leading to the development of chemoresistance and development of
the stem cell phenotype in these cells.
Besides CD44 and CD24, additional markers have recently been
identified to classify cancer stem cells. Of these, ALDH1 [14] has gained
importance as a potential marker of breast cancer stem cell phenotype
[15]. In support of published data, we have also identified an ALDH+
subpopulation in Twist-expressing breast cancer cells. Interestingly,
MDA-MB-231, which has very high CD44+/CD24−/low levels, exhibits
a negligible amount of ALDH+ cells (data not shown). This could be
either due to long-term growth in vitro or to the genetic heterogeneity
of the cell type.
Another feature of cancer stem cells is the propensity to form mam-
mospheres in culture. Our results using Twist-overexpressing cells to
form mammospheres are in close agreement with recently published
work using breast tumors, with the exception of MCF-7/Twist cells,
which did not result in the formation of the classic mammosphere
phenotype. The formation of such nonclassic mammosphere formation
Figure 7. Growth of low inoculums of purifiedCD44+/CD24−/low and
CD44+/CD24+ subpopulations in SCIDmice. (A) Graphical represen-
tation of growth rates of orthotopic xenograft tumors using flow-
sorted cells from the Twist+/CD44+/CD24−/low and CD44+/CD24+
subpopulations. We transplanted 100, 50, and 20 cells of the
Twist+/CD44+/CD24−/ low subpopulation, and 100 cells from the
Twist+/CD44+/CD24+ subpopulation. Fourmice per inoculumwere
used for this study. Significance was analyzed by a two-sided t-test
(**P< .05, ***P< .005). (B) Twist immunohistochemical staining of
representative tumors from the CD44+/CD24−/ low and CD44+/
CD24+ subpopulations. Photomicrographs were taken in bright
field settings at a magnification of ×40 using Nikon Eclipse 80i fluo-
rescence microscope.
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has been reported for the MDA-MB-231 cell line [35,40], which in-
triguingly exhibits a very high CD44+/CD24−/low subpopulation as well
as a high Twist expression. This would indicate that the phenomenon of
mammosphere generation is dependent on a number of factors such as
the degree of cellular differentiation, genetic makeup, and the biochemi-
cal parameters of the transformed cells. Furthermore, it is also possible
that Twist-induced breast cancer stem cells will be heterogeneous with
varying self-renewal capacity. This is supported by our data, which dem-
onstrate that the purified CD44+/CD24−/low subpopulation was able to
initiate tumor growth in the mammary fat pad with extremely low in-
oculums (20 cells) compared with the CD44+/CD24+ subpopulation.
This ability to form tumors from low inoculums conclusively demon-
strates that Twist is a primary driver of the breast cancer stem cell phe-
notype. More importantly, Twist expression was higher in the nucleus
of cells from the xenograft tumors generated by the CD44+/CD24−/low
subpopulation compared with those formed from the CD44+/CD24+
subpopulation. This indicates that the generation of breast cancer stem
cells by Twist expression results in a heterogeneous population of cells
with varying degrees of tumorigenicity andmay parallel to that observed
in breast cancer patient sample.
In conclusion, this is the first report of a single gene, Twist, being able
to promote the generation of breast cancer stem cells in a preclinical
model through the transcriptional regulation of CD24. This is a mech-
anistic finding that supports the paradigm of the relationship between
Twist expression and the acquisition of stem-like properties. In the fu-
ture, we hope to establish the utility of Twist expression as an additional
marker for breast cancer stem cells along with the more established
CD44+/CD24−/low/ALDH+ phenotype.
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